AbbVie Commits US$750 M Upfront to Oncology Collaboration with Genmab
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 6 (Table of Contents)
Published: 22 Jun-2020
DOI: 10.3833/pdr.v2020.i6.2544 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a bid to bolster its oncology portfolio, AbbVie has agreed to partner with Genmab to jointly develop and commercialise three of its clinical-stage antibody programmes: epcoritamab (DuoBody®-CD3xCD20), DuoHexaBody®-CD37 and DuoBody-CD3x5T4...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS